Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.

scientific article published on 26 October 2011

Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10549-011-1832-4
P698PubMed publication ID22037787

P50authorLaurence VanlemmensQ59690694
P2093author name stringCharles Fournier
Philippe Carpentier
Philippe Vennin
Jacques Bonneterre
Véronique Servent
Marie-Christine Baranzelli
Hélène Kolesnikov-Gauthier
P2860cites workPathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-upQ28306437
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study GroupQ33837310
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PETQ34048123
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancerQ36623843
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast GroupQ40510447
Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapyQ43201544
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapyQ45023411
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.Q46072247
The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancerQ46123246
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucoseQ46201991
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.Q46765380
Monitoring primary breast cancer throughout chemotherapy using FDG-PET.Q53525219
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.Q54671187
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectchemotherapyQ974135
Fluorodeoxyglucose Positron Emission TomographyQ130273243
P304page(s)517-525
P577publication date2011-10-26
P1433published inBreast Cancer Research and TreatmentQ326085
P1476titlePredictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course
P478volume131

Reverse relations

cites work (P2860)
Q36533964A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688
Q91744969A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
Q38165388Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer
Q38090509Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response
Q37254082Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results
Q38422342Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Q39612494FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies
Q87621688Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer
Q38059133Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.
Q28080621Role of positron emission tomography for the monitoring of response to therapy in breast cancer
Q47822633Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
Q28077678The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectives
Q53063063The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy.
Q34569318The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
Q53515259⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.

Search more.